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C-reactive protein (CRP) is a member of the pentraxin superfamily that is widely recog-
nized as a marker of inflammatory reactions and cardiovascular risk in humans. Recently, 
a growing body of data is emerging, which demonstrates that CRP is not only a marker 
of inflammation but also acts as a direct mediator of inflammatory reactions and the 
innate immune response. Here, we critically review the various lines of evidence suppor-
ting the concept of a pro-inflammatory “CRP system.” The CRP system consists of a 
functionally inert circulating pentameric form (pCRP), which is transformed to its highly 
pro-inflammatory structural isoforms, pCRP* and ultimately to monomeric CRP (mCRP). 
While retaining an overall pentameric structure, pCRP* is structurally more relaxed than 
pCRP, thus exposing neoepitopes important for immune activation and complement 
fixation. Thereby, pCRP* shares its pro-inflammatory properties with the fully dissociated 
structural isoform mCRP. The dissociation of pCRP into its pro-inflammatory structural 
isoforms and thus activation of the CRP system occur on necrotic, apoptotic, and isch-
emic cells, regular β-sheet structures such as β-amyloid, the membranes of activated 
cells (e.g., platelets, monocytes, and endothelial cells), and/or the surface of micro-
particles, the latter by binding to phosphocholine. Both pCRP* and mCRP can cause 
activation of platelets, leukocytes, endothelial cells, and complement. The localization 
and deposition of these pro-inflammatory structural isoforms of CRP in inflamed tissue 
appear to be important mediators for a range of clinical conditions, including ischemia/
reperfusion (I/R) injury of various organs, cardiovascular disease, transplant rejection, 
Alzheimer’s disease, and age-related macular degeneration. These findings provide the 
impetus to tackle the vexing problem of innate immunity response by targeting CRP. 
Understanding the “activation process” of CRP will also likely allow the development 
of novel anti-inflammatory drugs, thereby providing potential new immunomodulatory 
therapeutics in a broad range of inflammatory diseases.
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iNTRODUCTiON
C-reactive protein (CRP) is a member of the pentraxin superfam-
ily and was first discovered in 1930 by Tillett and Francis (1). 
Indeed, the first characterization of this protein was based on the 
initial observation that a distinct third fraction identified from the 
sera of patients with pneumococcus infection could precipitate 
the “C” polysaccharide derived from the pneumococcus cell wall. 
Subsequently, Avery and McCarty described CRP as an acute 
phase reactant after demonstrating that CRP levels were elevated 
in patients with a range of inflammatory conditions (2–4). Some 
40  years after the original description of CRP, phosphocholine 
(PC) was shown to be the specific ligand for CRP binding within 
the pneumococcal cell wall (5). Today, CRP is widely used in the 
clinic as a marker of inflammation (6).
However, importantly, there is now a large body of evidence 
from prospective clinical trials that CRP levels may serve as a 
predictor of cardiovascular events, thus bringing the biological 
role of CRP into focus (7–9). This review discusses how insights 
gained into the different structural isoforms of CRP have led to a 
greater appreciation of its pro-inflammatory and prothrombotic 
role, which is relevant to a broad range of disease states.
CRP STRUCTURe AND FUNCTiON
C-reactive protein is predominantly synthesized by the liver as a 
pentamer composed of five identical, non-covalently linked 23 kD 
protomers—each one folded into two antiparallel β-sheets with a 
“jelly roll” topology (10, 11). Each protomer has a binding face 
with a PC-binding site, which binds apoptotic cell membranes and 
bacterial cell walls (12). The two key residues of the hydrophobic 
binding pocket essential for mediating PC binding are Phe-66 
and Glu-81. Phe-66 regulates hydrophobic interactions with the 
methyl group of PC, while Glu-81 interacts with the positively 
charged nitrogen (12). The opposite face of the binding face, 
known as the effector face, binds the globular domain of the com-
plement factor 1q (C1q) and Fc gamma receptors, thus providing 
a mechanism to activate the innate immune system (13). However, 
the location of these binding sites on the pentameric form of CRP 
(pCRP) appears to be cryptic, thus supporting the concept that 
pCRP does not possess intrinsic pro-inflammatory properties.
CONFORMATiONAL CHANGe OF CRP 
CReATeS HiGHLY PRO-iNFLAMMATORY 
MOLeCULeS
pCRP dissociates into monomeric CRP (mCRP) after exposure to 
heat, urea, or an acidic microenvironment (14, 15). The dissocia-
tion of pCRP into its subunits exposes a range of neoepitopes that 
are likely to account for the distinct pro-inflammatory function of 
mCRP (16, 17) (see below). More recently, the in vivo generation 
and consequences of mCRP production have begun to be eluci-
dated. Indeed, we and others have demonstrated that pCRP can 
be dissociated by calcium-dependent binding to liposomes and 
cell membranes (16–18). Activated platelets (19), endothelial cells 
(20), and monocytes (17) may provide the requisite PC-binding 
sites to facilitate the dissociation of pCRP to mCRP. This process 
is phospholipase A2 dependent since PC exposure and hence 
pCRP dissociation are dependent upon PLA2 generation (20).
The dissociation of pCRP to mCRP also produces marked 
changes in the solubility of the respective structural isoforms. 
While pCRP is soluble, the dissociation produces a shift from a 
predominantly β-sheet tertiary protein conformation to protom-
ers with an α-helical tertiary structure and the exposure of previ-
ously cryptic interprotomer contacts (17). As such, mCRP has 
little solubility, and this led to the concept that this isoform was 
predominantly a tissue-bound form of CRP.
iDeNTiFiCATiON OF THe PRO-
iNFLAMMATORY pCRP* STRUCTURAL 
iSOFORM
Very recent work from our group has provided additional new 
insights into the mechanism of pCRP dissociation. The conforma-
tional change of pCRP that occurs on the PC-rich and highly 
curved MP membranes (derived from activated monocytes, 
platelets, or endothelial cells) initiates a spatial separation of the 
five CRP monomers in relation to each other (17). Therefore, 
MPs with bound, dissociated pCRP* act as transport vehicles of 
circulating pCRP* to distant sites. In this regard, microparticles 
with bound dissociated CRP can be detected in patients with 
acute coronary syndromes (21). In contrast, mCRP appears to be 
rapidly cleared from the circulation due to its unfolded and more 
disordered state. Moreover, while most studies have investigated 
the presence of mCRP as the dissociated structural isoform in 
inflamed tissue, we have shown that pCRP* is the dominant 
isoform in injured tissue, including inflamed human muscle, 
burn wounds, and human atherosclerotic plaques.
Crucially, both pCRP* and mCRP have pro-inflammatory 
functions; however, the structural isoform-specific antibodies 
commonly used to distinguish pCRP from dissociated isoforms 
cannot differentiate between mCRP and pCRP*. Although still 
existent as a pentamer, this intermediate form—termed pCRP*—
exposes functionally active neoepitopes, which are recognized by 
isoform-specific antibodies and allow the binding of C1q (1, 17). 
These studies have led to the concept of conformation-dependent 
regulation of the innate response by CRP. While pCRP does not 
display any pro-inflammatory properties, as discussed below 
both mCRP and pCRP* are potent pro-inflammatory structural 
isoforms of CRP, which can mediate immune, inflammatory, and 
prothrombotic responses in a range of diseases (Figure 1).
LOCATiON AND ReGULATiON OF CRP 
PRODUCTiON
The vast majority of CRP is produced in the liver (22). While the 
production of CRP has also been reported in an array of other 
cell types including leukocytes (23), adipocytes (24), neuronal 
cells (25), renal cells (26), and respiratory epithelial cells (27), the 
extrahepatic production of CRP is not thought to influence plasma 
CRP concentrations significantly. In health, plasma CRP levels 
may be undetectable; however, in the context of inflammation, 
FiGURe 1 | pCRP is produced by the liver in the context of inflammation and infection in response to cytokines such as interleukin 6 (IL-6) and IL-1β. pCRP can  
be dissociated into its pro-inflammatory structural isoforms [pCRP* and monomeric CRP (mCRP)] on the surface of activated platelets, leukocytes, endothelial  
cells, phosphocholine-rich MPs, dying cells, and beta-amyloid. pCRP* and mCRP can activate platelets, leukocytes, and endothelial cells, in addition to activating 
complement via C1q binding. The pro-inflammatory effects of pCRP*/mCRP can be inhibited with compounds such as bisPC that inhibit the dissociation of pCRP 
and block mCRP effector binding.
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they can increase by 1,000-fold within 24–72 h (28). Thus, the 
CRP plasma level is widely used as a marker in reporting on the 
general inflammatory status of patients (29–32).
The induction of CRP expression and secretion by hepatocytes 
is principally regulated by interleukin 6 (IL-6) and to a lesser extent 
interleukin 1β (IL-1β) (33). In contrast, interferon-α, statins, 
and nitric oxide suppress the induction of pCRP expression by 
pro-inflammatory cytokines, resulting in a weak correlation of 
serum CRP levels with viral infections or systemic lupus (34–36). 
Indeed, the pro-inflammatory cytokines induce hepatic produc-
tion of several acute phase proteins. This upregulation occurs via 
the transcriptional activation of the STAT3, C/EBP, and NF-κB 
pathways (33, 37, 38). In the context of CRP, the recruitment and 
activation of the C/EBP family members C/EBPβ and C/EBPα 
appear critical to the induction of CRP. Moreover, the STAT3 and 
Rel proteins bind to the proximal CRP promoter, with the ensuing 
interactions resulting in enhanced binding of C/EBP and thereby 
facilitating maximal CRP induction.
THe PRO-iNFLAMMATORY AND 
PROTHROMBOTiC PROPeRTieS OF CRP
As discussed, dissociated mCRP and pCRP* are considered 
the pro-inflammatory components of the “CRP system.” While 
most work has focused on the biological effects of mCRP, pCRP* 
exhibits similar effects. Consistent with this, mCRP has been 
demonstrated to activate monocytes, thus leading to Mac-1 
activation and resulting in enhanced monocyte adhesion in vitro 
(19). Moreover, mCRP-stimulated monocytes induce reactive 
oxygen species generation (19). While the binding of mCRP to 
monocytes is at least partially dependent upon the Fc gamma 
receptors (CD64, CD32, CD16), it also appears that lipid rafts are 
essential for mCRP binding since disruption of these with agents 
such as nystatin completely inhibits mCRP binding (39–41). 
In accordance with the pro-inflammatory properties of mCRP, 
neutrophils in response to mCRP stimulation upregulate Mac-1 
binding, which correlates with an increase in neutrophil adhesion 
on activated endothelial cells in  vitro (42). In addition, mCRP 
stimulates the production of interleukin 8 (IL-8) from neutro-
phils via intracellular peroxynitrite production (43).
Monomeric CRP can also activate endothelial cells (41, 44). 
Under normal conditions, the endothelium maintains a quies-
cent state to prevent the unwanted adhesion of platelets and 
leukocytes. However, upon activation, inflamed endothelium 
upregulates the expression of many adhesion receptors, which 
facilitate platelet and leukocyte interaction. Two of the main 
endothelial adhesion receptors, intercellular adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), are 
upregulated by endothelial cells in response to mCRP stimulation 
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(18, 41, 44). ICAM-1 serves as an important counter-receptor for 
the leukocyte integrin lymphocyte function-associated antigen 1 
and thereby enhances leukocyte recruitment to sites of endothe-
lial inflammation (45). Moreover, ICAM-1 can bind fibrinogen 
and thus serves as an important counter-receptor for the platelet 
integrin GPIIb/IIIa and thus mediates stable platelet adhesion 
to the inflamed endothelium (46). Likewise, VCAM-1 binds to 
the leukocyte integrin very late antigen 4 and serves to promote 
leukocyte adhesion (47). In addition, mCRP has been demon-
strated to stimulate endothelial chemokine production, with 
both IL-8 and monocyte chemoattractant protein-1 release being 
increased in the context of mCRP activation (41, 44, 48).
Platelets, which mediate thrombosis and hemostasis, also 
have important innate immune functions (49). In this regard, 
mCRP has been shown to activate platelets as demonstrated 
by its ability to induce GPIIb/IIIa activation and alpha granule 
exocytosis (as measured by P-selectin expression) in a process 
dependent upon p38 MAPK and JNK signaling (50, 51). The 
receptor responsible for mediating the prothrombotic effects 
of mCRP on platelets has not been clearly elucidated. However, 
the platelet scavenger receptor CD36 plays a vital role given 
that CD36 inhibition blocks some of the effects of mCRP (50). 
Interestingly, the membrane of activated platelets appears to 
be an essential substrate mediating pCRP dissociation and, in 
this context, growing thrombi in vitro can dissociate CRP, thus 
promoting thrombus growth (50, 51).
The complement cascade is an essential arm of the immune 
system. In keeping with the concept that mCRP modulates the 
innate immune response, mCRP can bind and activate the com-
plement system (52). mCRP and pCRP* readily bind to C1q and 
thus lead to robust activation of the classical complement cascade, 
which ultimately culminates in the formation of the membrane 
attack complex (17). Recent experimental work has demonstrated 
that the globular head of C1q can only bind to dissociated mCRP 
or spatially altered pCRP*, but not to pCRP, since this appears to 
represent the crucial structural determinant regulating comple-
ment activation (17). Given the highly conserved nature and 
universal presence of PC in eukaryotic cells, the ability of PC to 
bind CRP may serve to direct the opsonization of apoptotic and 
necrotic cells by the complement system, thus facilitating their 
clearance (28, 53, 54).
Interestingly, mCRP appears to demonstrate a dual role in 
regulating the complement system, since it not only serves to 
activate the complement cascade but also functions as a regulator 
of the degree of complement activation. In this regard, mCRP can 
also bind complement regulatory proteins such as Factor H and 
direct these to sites of cellular damage (55, 56). This process acts 
to enhance C3b inactivation, thus limiting the further generation 
of inflammatory products and aiding in the opsonization and 
subsequent clearance of damaged cells (55, 57). However, under 
pathological conditions, these responses may be maladaptive 
and promote the pathogenesis of inflammatory and immune 
conditions.
As will be discussed, these observations that pCRP* and mCRP 
can enhance innate immune responses have relevance to a range 
of clinical conditions and, as such, they may represent potentially 
novel therapeutic targets for a diverse spectrum of diseases.
CRP iN iSCHeMiA/RePeRFUSiON
Ischemia/reperfusion injury (IRI), referring to the restoration of 
blood flow to a previously ischemic organ, significantly contrib-
utes to morbidity and mortality in a range of clinical scenarios, 
including myocardial infarction and ischemic stroke (58). Indeed, 
experimental evidence suggests that up to 50% of the final infarct 
volume from myocardial infarction is due to reperfusion injury 
(59). One of the classic features of IRI is the initiation of a maladap-
tive immune response, which leads to widespread microvascular 
dysfunction and exacerbation of organ injury (58). A large body 
of data now exists demonstrating that CRP plays an active role in 
exacerbating IRI (Figure 2). The administration of pCRP to rats 
after the onset of myocardial ischemia has been shown to increase 
infarct volume by 40% in a complement-dependent manner (60). 
In accordance, pCRP administered to rats prior to the onset of 
cardiac reperfusion results in the marked deposition of mCRP 
in the infarcted myocardium, which correlates to the degree of 
leukocyte infiltration, apoptosis (as measured by caspase-3), and 
expression of IL-6 and TNF-alpha (20).
Critically, mCRP, but not pCRP, is abundant within infarcted 
human myocardium and also co-localizes with complement 
staining (20, 61). Our group has recently confirmed these obser-
vations in a rat model of IRI where rats administered pCRP dis-
played more severe renal tubular damage, which correlated with 
increased mCRP deposition, leukocyte infiltration, and caspase-3 
activation after IRI (manuscript under review). Interestingly, the 
effects of CRP here appear primarily dependent upon facilitating 
endothelial–leukocyte interactions and enhancing leukocyte 
ROS generation in a process linked to mCRP binding to leukocyte 
lipid raft domains. These findings are consistent with previous 
work utilizing transgenic mice that express human CRP where, 
after renal IRI, these mice displayed more severe renal injury 
associated with a diversion of the monocyte/macrophage profile 
away from a protective M2 profile toward a “pro-inflammatory,” 
deleterious M1 profile in the context of IRI (62).
Studies using intravital microscopy have been used to delineate 
the spatiotemporal aspects of CRP conformational changes in 
the context of tissue inflammation. mCRP becomes deposited 
on apoptotic endothelial cells after LPS challenge, and this leads 
to enhanced leukocyte rolling, adhesion, and transmigration 
(20). CRP is also transported into the inflamed tissue by trans-
migrating leukocytes, with leukocyte infiltrates in inflamed 
tissue co-localizing with mCRP deposition (17, 20). These 
pro-inflammatory effects of CRP are principally complement-
dependent, since depletion of complement in vivo is associated 
with a marked inhibition of leukocyte adhesion in the context 
of exogenous pCRP administration. Moreover, monocytes in rats 
administered exogenous pCRP in the context of LPS-induced 
endothelial inflammation also demonstrated increased ROS 
generation in  vivo, thus demonstrating another mechanism, in 
addition to complement activation, by which mCRP can mediate 
tissue damage (20). In accordance with these in  vivo findings, 
sections of human striated muscle, which have undergone IRI 
also demonstrated strong mCRP staining, which co-localized 
with monocytes/macrophages (20). Interestingly, recent findings 
from our group demonstrate that circulating pCRP binds to the 
FiGURe 2 | In the setting of myocardial ischemia, the hepatic production of pCRP is upregulated under the regulation of interleukin 6 (IL-6). pCRP circulates in the 
blood, where it can interact with MPs, activated platelets, leukocytes, and endothelial cells in the ischemic myocardium, which triggers the dissociation of pCRP to 
its pro-inflammatory forms pCRP* and monomeric CRP (mCRP). In turn, these pro-inflammatory structural isoforms of CRP aggravate tissue injury by promoting the 
adhesion of leukocytes and platelet deposition to the ischemic endothelium, ultimately resulting in the formation of microvascular thrombi and thus microvascular 
obstruction. In addition, pCRP*/mCRP enhances leukocyte transmigration where infiltrating leukocytes degranulate and exacerbate tissue injury. pCRP*/mCRP also 
activate complement, which can directly mediate tissue injury via formation of the membrane attack complex. These pro-inflammatory effects of CRP ultimately 
result in enhanced myocardial injury and impaired organ function.
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cell membrane of LPS-activated, but not resting, monocytes 
in vitro and in vivo (17). Here, CRP binds to stimulated mono-
cytes, which release pro-inflammatory microvesicles loaded with 
pCRP*, thus allowing binding of the complement factor C1q and 
ultimately causing complement activation.
The acidic pH at sites of inflammation or ischemia can also lead 
to exposure of CRP neoepitopes (14–16). Emphasizing the broad 
biological relevance of CRP deposition and dissociation in dam-
aged tissue, CRP has also been demonstrated to co-localize with 
complement factor C3d and leukocytes in tissue samples from 
burned wounds (63). Moreover, mCRP deposition has not only 
been found exclusively in areas of damaged tissue co-localized 
with CD68-positive monocytes and complement but also corre-
lates with the predicted burn depth (64). Complementary in vitro 
data suggest that mCRP opsonizes necrotic cells and accelerates 
phagocytosis by macrophages (64). These observations, combined 
with previous data supporting a role of complement in mediat-
ing wound healing, suggest that the role of mCRP in this context 
likely extends beyond its direct pro-inflammatory effects and it 
may promote wound scarring and contracture development.
CRP iN ALLOGeNeiC TRANSPLANTATiON
Allogeneic solid organ transplantation is a curative therapy for 
patients with end-stage organ failure. Despite improvements in 
immunosuppressive protocols and supportive care, close to half of 
all patients lose their allografts within 10 years after transplantation 
due to chronic graft rejection and graft dysfunction (65). Based 
on multiple retrospective studies of human kidney transplanta-
tion, an acute rejection episode has been shown to be associated 
with a significantly decreased 1-year graft survival (66, 67), in 
addition to being linked to adverse long-term survival and graft  
outcomes (68).
Allograft rejection triggered by major histocompatibility com-
plex incompatibility is dependent on T-cell activation. However, 
it has recently been demonstrated that innate recognition of allo-
geneic non-self by the recipient’s monocytes can also initiate graft 
rejection (69). Importantly, it is now apparent that other factors 
such as IRI play a critical role in mediating the immune response 
to allogeneic transplantation. In solid organ transplantation, the 
impacts of IRI on both acute rejection and long-term allograft 
survival have been extensively investigated (70–72). For instance, 
increased rates of acute rejection episodes have been reported 
in experimental renal transplant models when ischemic times 
were prolonged (73) and large clinical trials have shown that the 
duration of cold ischemia time adversely correlates with allograft 
survival (72, 74). However, the relevance of the innate response to 
acute and chronic rejection in allogeneic transplantation is poorly 
understood.
Donor endothelial cells are the predominant target of the allo-
immune response because these cells represent the first barrier to 
the recipient’s immune system. Thus, allograft rejection typically 
manifests in the microvasculature of the transplanted tissue (75). 
IRI generates damage-associated molecular patterns (DAMPs) such 
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as heat shock proteins and ROS, heparin sulfate, or fibrinogen (76). 
DAMPs, in turn, can bind and activate toll-like receptors, which 
results in a strong inflammatory response and release of IL-1β, IL-6, 
and tumor necrosis factor, as well as CRP production (77).
With respect to the pro-inflammatory effects of CRP and its 
contribution to postischemic tissue injury, we have investigated 
the impact of CRP on innate allogeneic recognition and graft 
rejection in a hind limb transplantation model in rats (unpub-
lished data). Based on our previous studies, we hypothesized that 
CRP-aggravated tissue damage and inflammation are associated 
with higher rates of acute and chronic rejection. Furthermore, 
we investigated the potential of inhibiting the conformational 
change of pCRP with bisPC as a therapeutic target for allogeneic 
transplantation in vivo. In our study, the administration of pCRP 
significantly accelerated clinical allograft rejection. We identified 
that the tissue damage-induced conformational change of pCRP 
led to increased systemic activation and localized transmigration 
of monocyte subpopulations. Most importantly, the stabilization 
of pCRP with bisPC abrogated its immunomodulatory effects 
and consequently inhibited aggravation of the acute transplant 
rejection (unpublished data). Thus, the inhibition of pCRP 
dissociation represents a promising, novel immunomodulatory 
therapeutic strategy in allogeneic solid organ transplantation.
CRP iN ATHeROSCLeROSiS
Inflammation incites and promotes the progression of atheroscle-
rosis (78). In this regard, the role of CRP as a biomarker reflecting 
cardiovascular risk has received much attention (79, 80). Supporting 
the concept that CRP may reflect cardiovascular risk, data from the 
Women’s Health Study and Physicians’ Health Study demonstrated 
that CRP is a strong predictor of future cardio vascular events 
(81, 82). Moreover, the large-scale JUPITER trial has shown that 
treating patients with asymptomatic elevations in CRP provides 
benefit in reducing the cardiovascular event rate and death (7). 
Most interestingly, in the recent highly publicized CANTOS trial, 
the extent of the reduction of CRP achieved with the anti-Il-1β 
antibody canakinumab correlated directly with the extent of reduc-
tion in primary endpoint events, mainly myocardial infarction (8).
However, some controversy persists regarding whether CRP is a 
useful predictive biomarker in cardiovascular disease and this may 
reflect the fact that standard assays measure total CRP, rather than 
explicitly measuring the pro-inflammatory monomeric structural 
isoform (83). Aside from acting as a potential biomarker for 
cardiovascular disease, there is now a wealth of experimental data 
suggesting a direct causative role for CRP in promoting cardiovas-
cular disease. Indeed, vulnerable plaques have been demonstrated 
to release CRP, which correlated with neutrophil Mac-1 activation 
(84). Additionally, CRP is present within atherosclerotic plaques 
and here is co-localized with macrophages, complement, and 
oxidized LDL (85). Significantly, we have demonstrated that 
mCRP, but not pCRP, is present within atherosclerotic plaques 
and that mCRP-bearing microparticles are significantly increased 
in patients with acute coronary syndromes (19, 21). Importantly, 
mCRP, but not pCRP, is detected within infarcted human myocar-
dium, where it co-localizes with macrophages (20). More recently, 
in vivo work has demonstrated that mCRP accumulates at sites of 
endothelial inflammation and this results in enhanced leukocyte 
adhesion and transmigration (17). Demonstrating the importance 
of mCRP in exacerbating tissue injury, inhibition of pCRP dis-
sociation with bisPC has been shown to reduce infarct size in a rat 
model of myocardial infarction (86).
These findings support the concept that mCRP may not only 
be a valuable biomarker in cardiovascular disease but also directly 
acts to promote a deleterious inflammatory response in the con-
text of atherogenesis and myocardial infarction.
CRP iN ALZHeiMeR’S DiSeASe (AD)
Alzheimer’s disease represents the leading cause of dementia 
(87). The underlying pathogenesis of AD appears to involve 
the accumulation of amyloid beta (Aβ) plaques in extracellular 
spaces and within the walls of the vasculature (88). The later 
stages of AD typically involve the accumulation of neurofibrillary 
tangles—comprised of Tau protein aggregates—in neurons (89). 
Previous studies have demonstrated that neuronal tissue from 
patients with AD expresses higher amounts of CRP compared 
to non-AD controls and that CRP staining co-localizes with 
senile plaques (90, 91). Recently, evidence is beginning to emerge 
that CRP may actively contribute to the pathogenesis of AD. Aβ 
plaques can dissociate pCRP in vitro and, in accordance with this, 
mCRP and C1q are observed to co-localize with Aβ plaques in 
human AD sections (92).
Supporting the concept that mCRP may directly contribute to 
AD pathogenesis, recent data demonstrate that the hippocampal 
injection of mCRP in a mouse model of AD induces cognitive 
decline and behavioral changes (93). These features correlate with 
structural changes, with mCRP-treated mice displaying enhanced 
p-Tau and p-β amyloid plaque production (93). mCRP has also 
been demonstrated to induce Tau filament polymerization and 
directly trigger potentially neurodegenerative signaling path-
ways in rat cortical neurons in vitro. Interestingly, mCRP is also 
abundant within the microvasculature of patients with AD and 
co-localizes with β amyloid and CD105 (93). This observation 
appears most prominent in patients with prior ischemic stroke, 
which raises the interesting possibility that mCRP deposition in 
these regions promotes dysregulated angiogenesis and, therefore, 
promulgates the small vessel vasculopathy characteristic of AD.
CRP iN AGe-ReLATeD MACULAR 
DeGeNeRATiON (AMD)
Age-related macular degeneration is a leading cause of blindness 
in developed countries (94). It has previously been demonstrated 
that elevated CRP levels serve as an independent risk factor for 
the development and progression of AMD (95). Recently, it was 
shown that mCRP plays a potentially crucial pathogenic role in 
patients with the high-risk CFH SNP (Y402H) (96). This SNP 
involving the CFH gene is considered one of the most significant 
genetic risk factors for AMD development (97). Indeed, levels of 
mCRP, but not pCRP, are increased in the choroid of patients with 
the high-risk CFH mutation (96). Moreover, the application of 
mCRP to choroidal endothelial cells in vitro results in enhanced 
endothelial cell permeability and migration, both of which are 
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important for AMD development (96). Further supporting the 
notion that mCRP may promote AMD development, human 
choroidal tissue exhibits an altered transcriptome in response to 
mCRP stimulation. The expression of both ICAM-1 and carbonic 
anhydrase 4 (CA4) is altered at the mRNA and protein level, with 
mCRP resulting in increased ICAM-1 expression and decreased 
CA4 (96). These are important observations, given that these 
changes are observed in patients with AMD and are linked to the 
development of AMD (98, 99).
THeRAPeUTiC TARGeTiNG OF CRP
The powerful pro-inflammatory properties of pCRP* and mCRP 
in mediating a broad range of disease states make inhibition of 
CRP an attractive therapeutic strategy. In this regard, 1,6 bis-
phosphocholine (bisPC) has previously been shown to amelio-
rate the deleterious effects of CRP in mediating myocardial IRI 
(20, 86). Indeed, bisPC prevents mCRP formation and 
deposition in infarcted myocardium in addition to preserving 
myocardial function in the context of IRI. bisPC abrogates the 
pro-inflammatory effects of CRP by binding to and preventing 
CRP dissociation, in addition to blocking the binding of pCRP to 
MPs, thus inhibiting the interactions of CRP with complement 
(17, 86). However, the pharmacokinetic profile of bisPC is unfa-
vorable, given its relatively low affinity for CRP (Kd = 150 nM) 
and relatively short half-life of 90 min in mice (86). Therefore, 
there remains much interest in developing novel, more potent 
inhibitors of CRP with improved bioavailability.
PeRSPeCTive
Deepening our understanding of the role of CRP, as an essential 
arm of the innate immune response and a central player in the 
pathogenesis of a range of inflammatory conditions, will be vitally 
important in translating potential anti-inflammatory, anti-CRP 
approaches to the clinic. However, to date, an important limita-
tion in exploring the direct effects of CRP inhibition in these 
chronic diseases is the lack of suitable mouse models. Currently, 
the most widely used approach to study the role of CRP in vivo 
is the exogenous administration of pCRP to mice or rats prior to 
an acute inflammatory challenge. This is due to basic phylogenic 
differences in CRP biology between rodents and humans. For 
example, mice express very low levels of CRP, while rat CRP 
cannot activate complement (100, 101).
Therefore, while the administration of exogenous human 
CRP to rodents has afforded essential insights regarding CRP 
biology, it does not allow for in vivo mechanistic studies of CRP 
in chronic inflammatory conditions such as IRI, transplant 
rejection, atherosclerosis, or AMD. Thus, the development 
of novel animal models that express human CRP will allow 
more detailed studies regarding the precise mechanism of CRP 
dissociation in inflammation and its potential role as a novel 
therapeutic target.
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